Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JMM who wrote (5093)	8/6/1998 3:38:00 PM
From: scaram(o)uche	Respond to of 6136

>> the real days of shooting forever higher may be over << Don't think that too many here will disagree with that. With respect to "one product company", it certainly is true. It's simply an issue of whether that one product, the research and marketing infrastructure, and the preclinical and clinical studies are discounted. I've worked/coordinated biotech deals for a large pharma. I am very confident of my opinion, but it's just that.... opinion.

To: JMM who wrote (5093)	8/12/1998 1:41:00 PM
From: JMM	Read Replies (1) \| Respond to of 6136

.......if I were to pick a possible low for this stk based on a worse case scenario...I would look to 15 or 16 as the low. Split adjusted its from around those levels that the major jump in its price occured from in the past. The shorts have barely budged so far even with the stk down a great deal...still over 7 million out there. I would look for cover at those levels which may bring the price back to the 20s....but not really the squeeze on the shorts that people have hoped for.